TESAMORELIN.XYZ explains a lab-made copy of the hormone that tells the pituitary to release growth hormone. We sell nothing here.
Tesamorelin
.XYZ
Burnt orange illustration of a long wavy chain of beads with signal rings on a dark background
GHRH ANALOGUE · 44 AMINO ACIDS · TH9507

Tesamorelin.
A Signal to the Pituitary

Your brain uses a small hormone to tell the pituitary gland when to release growth hormone. Tesamorelin is a sturdier, lab-made version of that hormone. In 2010 it became the first US medicine for the deep belly fat that some people with HIV build up on treatment. This guide covers what it is, what the trials found and why Europe said no.

Read the Basics Go to the Research
Tesamorelin is a prescription medicine in the US and Canada for one specific use. It has no marketing authorisation in the EU or the UK. Research-grade tesamorelin is meant for laboratory work only, and nothing here is medical advice.
A chain of 44 amino acids
FDA approval in 2010
Not licensed in the EU or UK

Why People Talk About It

Tesamorelin was created by Theratechnologies, a drug company in Montreal, under the code TH9507. The team took the full natural form of growth hormone-releasing hormone, or GHRH, and added a small chemical cap to one end so the body would not break it down so fast.

Modern HIV medicines saved millions of lives, but some people on them gained fat deep inside the abdomen, around the organs, while their arms and legs grew thinner. This visceral fat is linked to heart and liver problems. Tesamorelin was tested as a way to shrink it by nudging the body to make more of its own growth hormone.

Two large trials led to US approval under the brand name Egrifta. European regulators were less convinced, and the application there was withdrawn in 2012. Since then, researchers have looked at fatty liver, memory and physical fitness. The pages below go through it step by step.

Key Facts

What it isA synthetic copy of human GHRH (all 44 amino acids) with an extra chemical group that makes it last longer
Other namesTH9507 and tesamorelin acetate; brand names Egrifta, Egrifta SV and Egrifta WR
Molar massAbout 5,136 g/mol
TargetGHRH receptors on the pituitary gland, which then releases growth hormone
Approved useUS and Canada: reducing excess abdominal fat in adults with HIV and lipodystrophy
CompanyDeveloped by Theratechnologies; the company was bought by Future Pak in September 2025
StatusNo marketing authorisation in the EU or the UK

A Quick Reminder

This site informs; it does not advise. Research-grade tesamorelin is not made for human use. If you are worried about belly fat, your liver or your hormones, speak to a doctor.

What You Will Find Here

What Is Tesamorelin?
How tesamorelin talks to the pituitary and what follows
→
History
From a Montreal lab to Egrifta, and the European withdrawal
→
Research
Belly fat, liver fat and memory: what the trials measured
→
Rules & Safety
Where it is approved, side effects and who should avoid it
→
Sourcing
Points laboratories check before buying
→